Anticancer Bioscience, a company developing synthetic lethal approaches to precision oncology, have relocated to Tianfu International Biotown, in Chengdu, China, to accommodate its growth and expansion, and on the back of its recent financing. Biotown is considered the premier biotech research park in Chengdu, the capital of Sichuan province.
The new facility is three times larger than the company’s previous site. With a total research space of approximately 40,000 square feet across four floors, the new facilities will include offices and laboratories for Natural Product Library and Natural Product Drug Design, Analytical Chemistry, Pre-formulation Research, DMPK, Computational Chemistry and Drug Design, Cell Culture, HTS/HCS, Target MOA, Pharmacology & Toxicology, Laboratory Animal Resource Center (LARC), Small Animal In vivo Imaging and Medicinal Chemistry.
In October 2021, ACB announced that it had secured an additional CNY 68.4 million (around US$10.6 million) from new Chinese investors, led by Three Rivers Capital. The total raised in the seed round is now over CNY 200 million (around US$31 million).
Drug discovery programmes
With five drug discovery programmes, ACB is progressing rapidly through optimisation to candidate selection toward IND enabling studies, with the aim of initiating two clinical trials in the US in 2022.
Dr Yang, President and CEO of ACB, said: “We are delighted to be part of China’s prestigious Biotown community, as neighbors to pharma companies including AstraZeneca and Johnson & Johnson, and many other innovation-driven biotech companies. We will continue to make full use of the excellent locational advantages, such as the region’s rich natural product resources, and the local government’s commitment to building up biotech companies, to support our work in translating scientific breakthrough into effective medicines. We will be proud to launch our first programmes into human clinical trials from our new corporate headquarters in Biotown”.
Image credit: Anticancer Bioscience